Deutsche Bank
CTMX icon

Deutsche Bank’s CytomX Therapeutics CTMX Stock Holding History

Deutsche Bank’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49M Buy
663,038
+199,617
+43% +$762K ﹤0.01% 1770
2026
Q1 		$2.18M Buy
+463,421
New +$2.35M ﹤0.01% 1732
2022
Q2 		– Sell
-38,145
Closed -$102K – 4160
2022
Q1 		$102K Sell
38,145
-4,178
-10% -$16K ﹤0.01% 3573
2021
Q4 		$183K Buy
42,323
+2,474
+6% +$14.5K ﹤0.01% 3429
2021
Q3 		$203K Sell
39,849
-661
-2% -$3.54K ﹤0.01% 3561
2021
Q2 		$257K Sell
40,510
-843
-2% -$6.56K ﹤0.01% 3638
2021
Q1 		$320K Sell
41,353
-45,976
-53% -$364K ﹤0.01% 3374
2020
Q4 		$572K Sell
87,329
-29,565
-25% -$211K ﹤0.01% 2819
2020
Q3 		$777K Buy
116,894
+56,008
+92% +$415K ﹤0.01% 2358
2020
Q2 		$507K Buy
60,886
+7,504
+14% +$69.7K ﹤0.01% 2633
2020
Q1 		$410K Sell
53,382
-124,417
-70% -$867K ﹤0.01% 2581
2019
Q4 		$1.48M Sell
177,799
-20,099
-10% -$136K ﹤0.01% 2151
2019
Q3 		$1.46M Sell
197,898
-85,412
-30% -$843K ﹤0.01% 2094
2019
Q2 		$3.18M Buy
283,310
+231,479
+447% +$2.43M ﹤0.01% 2077
2019
Q1 		$554K Buy
51,831
+25,551
+97% +$378K ﹤0.01% 3382
2018
Q4 		$395K Sell
26,280
-175,028
-87% -$2.6M ﹤0.01% 3483
2018
Q3 		$3.73M Buy
201,308
+106,385
+112% +$2.42M ﹤0.01% 2425
2018
Q2 		$2.17M Buy
94,923
+10,939
+13% +$279K ﹤0.01% 2888
2018
Q1 		$2.39M Buy
83,984
+12,415
+17% +$354K ﹤0.01% 2743
2017
Q4 		$1.51M Sell
71,569
-126,762
-64% -$2.63M ﹤0.01% 2928
2017
Q3 		$3.6M Buy
198,331
+93,048
+88% +$1.45M ﹤0.01% 2122
2017
Q2 		$1.63M Buy
105,283
+77,315
+276% +$1.17M ﹤0.01% 2691
2017
Q1 		$482K Buy
27,968
+15,572
+126% +$205K ﹤0.01% 3091
2016
Q4 		$136K Buy
12,396
+9,025
+268% +$109K ﹤0.01% 3909
2016
Q3 		$52K Buy
3,371
+229
+7% +$2.77K ﹤0.01% 4200
2016
Q2 		$31K Buy
3,142
+1,970
+168% +$22.5K ﹤0.01% 4603
2016
Q1 		$15K Sell
1,172
-756
-39% -$10.5K ﹤0.01% 4711
2015
Q4 		$39K Buy
+1,928
New +$30.5K ﹤0.01% 4512

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Deutsche Bank's CTMX Position: Q2 2026 in Review

Deutsche Bank increased its CytomX Therapeutics (CTMX) stake by 43% in Q2 2026, buying an estimated $762K and bringing the position to 663,038 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1770.

Deutsche Bank first reported a position in CTMX in Q4 2015 and has held it in 28 quarters since. The position peaked at $3.73M in Q3 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Deutsche Bank held 663,038 shares of CytomX Therapeutics worth $2.49M as of Q2 2026.
  • Deutsche Bank bought 199,617 CytomX Therapeutics shares in Q2 2026, an estimated $762K.
  • CytomX Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1770 holding.
  • Deutsche Bank first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 28 quarters since.
  • Deutsche Bank's CytomX Therapeutics position peaked at $3.73M in Q3 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.